RS49960B - Postupak za regulisanje smanjenja aktivnosti osteoprotegerinskog liganda - Google Patents

Postupak za regulisanje smanjenja aktivnosti osteoprotegerinskog liganda

Info

Publication number
RS49960B
RS49960B YUP-197/01A YU19701A RS49960B RS 49960 B RS49960 B RS 49960B YU 19701 A YU19701 A YU 19701A RS 49960 B RS49960 B RS 49960B
Authority
RS
Serbia
Prior art keywords
opgl
polypeptide
animal
analog
ligand activity
Prior art date
Application number
YUP-197/01A
Other languages
English (en)
Inventor
Torben Halkier
Jesper Haaning
Original Assignee
Pharmexa A/S.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa A/S., filed Critical Pharmexa A/S.,
Publication of YU19701A publication Critical patent/YU19701A/sh
Publication of RS49960B publication Critical patent/RS49960B/sr

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Upotreba - OPGL polipeptida životinjskog porekla ili njegove podsekvence, ili - analoga OPGL koji je izveden iz životinjskog OPGL polipeptida u koji je uvedena modifikacija koja rezultuje u tome da imunizacija životinje analogom indukuje proizvodnju antitela na životinjski OPGL polipeptid, za dobijanje farmaceutske kompozicije koja sadrži OPGL polipeptid, podsekvencu ili analog za smanjenje OPGL kod životinja, naznačen time, što je OPGL polipeptid, autologni-protein za lečenje, prevenciju ili poboljšanje osteoporoze ili drugih stanja koje karakteriše prekomerna resorpcija kostiju. Prijava sadrži 7 zavisnih i 28 nezavisnih zahteva.
YUP-197/01A 1998-09-15 1999-09-13 Postupak za regulisanje smanjenja aktivnosti osteoprotegerinskog liganda RS49960B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801164 1998-09-15
US10289698P 1998-10-02 1998-10-02

Publications (2)

Publication Number Publication Date
YU19701A YU19701A (sh) 2005-06-10
RS49960B true RS49960B (sr) 2008-09-29

Family

ID=27675500

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-197/01A RS49960B (sr) 1998-09-15 1999-09-13 Postupak za regulisanje smanjenja aktivnosti osteoprotegerinskog liganda

Country Status (4)

Country Link
CN (1) CN101260152A (sr)
EA (1) EA006940B1 (sr)
RS (1) RS49960B (sr)
ZA (1) ZA200102131B (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
CN110923266A (zh) * 2019-11-07 2020-03-27 苏州工业园区唯可达生物科技有限公司 一种重组病毒载体、包含其的免疫组合物以及用途

Also Published As

Publication number Publication date
YU19701A (sh) 2005-06-10
ZA200102131B (en) 2002-06-14
EA006940B1 (ru) 2006-06-30
EA200100356A1 (ru) 2001-08-27
CN101260152A (zh) 2008-09-10

Similar Documents

Publication Publication Date Title
AR012540A1 (es) COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN
BR9812965A (pt) Métodos para tratamento de estados hipercoaguláveis ou deficiência de proteìna c adquirida
BR0317896A (pt) Complexos de cristais de proteìna e polìmeros iÈnicos
BR0107613A (pt) Bloqueio do crescimento de axÈnios mediado por receptor nogo
ATE205366T1 (de) Verfahren zur stabilisierung von proteinen in saurer umgebung mittel hoch veresterter pektine
DK0473724T3 (da) Et humant cytokin, interleukin-9
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE291628T1 (de) Verfahren zur hemmung der aktivität von osteoprotegerin-liganden
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
BR8603315A (pt) Processo para produzir um implante de liberacao controlada;implante usado no processo;processo para purificar e concentrar hormonio de crescimento biologicamente ativo em uma forma adequada para incorporacao em um implante para administracao subcutanea
ES2141229T3 (es) Productos farmaceuticos de proteinas y peptidos modificados.
KR910700264A (ko) 소마토트로핀 유사물
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
BR9912409A (pt) Processos de vacinação de uma ave doméstica, deredução de contaminação microbiana de avesdomésticas e de distribuição de uma proteìna emuma ave doméstica
ATE203413T1 (de) IMPFSTOFFE BESTEHEND AUS PROTEIN- ODER PEPTID- ßCOCHLEATENß UND DEREN VERWENDUNG ZUR IMMUNISIERUNG
Arnett Osteoclast biology
BR9909958A (pt) Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos
DE68917324D1 (de) Methode zur Immobilisierung von physiologisch aktiven Substanzen.
DE69934110T8 (de) Monomeres mp52/gdf-5 mit knochenmorphogener aktivität, und dieses enthaltende arzneimittel, zur vorbeugung und behandlung von knochen- und knorpelerkrankungen
ES549115A0 (es) Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
RS49960B (sr) Postupak za regulisanje smanjenja aktivnosti osteoprotegerinskog liganda
DE69535263D1 (de) Angiotensin ii zur verbesserung der befruchtung
ATE322906T1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
BRPI9916549B8 (pt) Composição farmacêutica, proteína, polinucleotídeo